Search results
Europe OKs Marketing of Hemophilia A Drug
Medscape· 3 days agoAltuvoct is used to treat and prevent bleeds and for perioperative prophylaxis in people of all ages with hemophilia A.
European Commission grants Sobi® Marketing Authorisation for ALTUVOCT™ for treatment of haemophilia...
Morningstar· 4 days agoSTOCKHOLM, June 19, 2024 /PRNewswire/ -- Sobi® today announced the European Commission has granted Marketing Authorisation for ALTUVOCT™ (efanesoctocog alfa), for the treatment and prevention of bleeds and perioperative prophylaxis in haemophilia A.
Sobi scores EU approval for haemophilia A replacement therapy Altuvoct
Pharmaceutical Technology via Yahoo Finance· 4 days agoAltuvoct acts as a high-sustained recombinant factor VIII replacement therapy, which is administered...
ISTH Releases Evidence-Based Clinical Practice Guideline for Hemophilia Treatment
The Tomahawk· 2 days agoHemophilia, a rare bleeding disorder resulting from deficiencies in blood coagulation factors, affects hundreds of thousands individuals worldwide and demands intricate management ...
Factor One Source Pharmacy to Pay $515,000 to Settle EEOC Disability and Genetic Information...
JD Supra· 6 days agoFactor One Source Pharmacy, LLC, a pharmacy providing specialized pharmacy services to patients...
ECU Health camps offer summer fun and care for children with chronic illnesses
News Channel 12 New Bern· 3 days agoWhile most kids are enjoying camp this Summer, there are those that cannot due to cancer, hemophilia...
Pfizer Lingers Near 11-Year Low Despite Promising Cancer Drug Updates — Is It A Sell?
Investor's Business Daily· 3 days agoU.S. regulators also approved Pfizer's gene therapy for hemophilia B, Beqvez. It will cost $3.5...
Should You Hold BioMarin Pharmaceutical (BMRN) Despite Setback?
Insider Monkey via Yahoo Finance· 3 days agoScout Investments, Inc, an affiliate of Carillon Tower Advisers, released the “Carillon Scout Mid...
FDA expands approval of first gene therapy for rare form of muscular dystrophy
KTBS Shreveport· 3 days agoElevidys, from the biotech company Sarepta Therapeutics – was approved to treat only children ages 4 and 5 with Duchenne muscular dystrophy, one of the most severe forms of inherited muscular ...
FDA lifts hold on PTC Huntington’s disease trial
BioPharma Dive via Yahoo Finance· 3 days agoBut the outlook for UniQure’s gene therapy isn’t straightforward, as patients who received its one-time therapy saw their mutant huntingtin levels...